| hydrochlorothiazide / Generic mfg. |
| Completed | 3b | 241 | RoW | Fimasartan or Fimasartan/Hydrochlorothiazide, Perindopril or Perindopril/Indapamide | Boryung Pharmaceutical Co., Ltd | The Elderly (≥ 70 Years) With Essential Hypertension | 08/19 | 12/19 | | |
| Completed | 3 | 233 | US | hydrochlorothiazide, diet, potassium supplementation, diet, magnesium supplementation, triamterene, chlorthalidone | University of California, San Francisco, National Heart, Lung, and Blood Institute (NHLBI) | Cardiovascular Diseases, Death, Sudden, Cardiac, Heart Arrest, Heart Diseases, Hypertension | 09/89 | | | |
NCT00886600: A Study to Investigate the Magnitude and Duration of Response of MK0954 Compared to Placebo in Patients With Hypertension (0954-021)(COMPLETED) |
|
|
| Completed | 3 | 122 | US | losartan potassium, MK0954, Comparator: placebo, hydrochlorothiazide (HCTZ), HCTZ | Merck Sharp & Dohme LLC | Hypertension | 05/92 | 08/92 | | |
NCT00642096: Factorial Study of Metoprolol Succinate TOPROL-XL (324A) |
|
|
| Completed | 3 | 1900 | US | Metoprolol Succinate, TOPROL-XL, Hydrochlorothiazide | AstraZeneca | High Blood Pressure (Hypertension). | 07/04 | 07/04 | | |
NCT00241007: A Study Comparing Valsartan With And Without Hydrochlorothiazide In Patients With Hypertension |
|
|
| Completed | 3 | 836 | US | VALSARTAN, VALSARTAN+HYDROCHLOROTHIAZIDE | Novartis | Hypertension | 03/05 | 03/05 | | |
NCT00171535: Efficacy and Safety of Valsartan/Amlodipine Combination in Patients With Severe Hypertension |
|
|
| Completed | 3 | 130 | US | valsartan/amlodipine | Novartis | Hypertension | 04/05 | 04/05 | | |
| Completed | 3 | 212 | Europe | valsartan plus hydrochlorothiazide | Novartis | Hypertension | 04/05 | 04/05 | | |
| Completed | 3 | 645 | US, Canada, Europe, RoW | Irbesartan/HCTZ, Avapro, Irbesartan monotherapy | Bristol-Myers Squibb, Sanofi | Hypertension | 05/05 | 05/05 | | |
| Completed | 3 | 2333 | Europe | placebo, olmesartan medoxomil, olmesartan medoxomil oral tablets, hydrochlorothiazide oral tablets | Sankyo Pharma Gmbh | Essential Hypertension | 06/05 | 06/05 | | |
NCT00219024 / 2004-000240-25: Clinical Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Hydrochlorothiazide in Patients With Essential Hypertension. |
|
|
| Completed | 3 | 2775 | US, Europe | aliskiren | Novartis | Hypertension | 06/05 | 06/05 | | |
| Completed | 3 | 496 | US, Canada, Europe, RoW | Irbesartan/HCTZ, Avapro, Irbesartan monotherapy, HCTZ monotherapy | Bristol-Myers Squibb, Sanofi | Hypertension | 06/05 | 06/05 | | |
| Completed | 3 | 2714 | Europe | valsartan plus hydrochlorothiazide | Novartis | Hypertension | 07/05 | 07/05 | | |
NCT00219037: Long Term Safety of Aliskiren Alone or With the Optional Addition of Hydrochlorothiazide in Patients With Essential Hypertension |
|
|
| Completed | 3 | 1955 | Europe | aliskiren | Novartis | Hypertension | 10/05 | 10/05 | | |
NCT00219154 / 2004-004015-38: A Clinical Study to Compare Long-term Efficacy and Safety of an Aliskiren Based Regimen to a Hydrochlorothiazidebased Treatment Regimen With Optional Addition of Amlodipine |
|
|
| Completed | 3 | 1125 | Europe | aliskiren | Novartis | Hypertension | 01/06 | 01/06 | | |
NCT00171405: A Clinical Study to Evaluate the Long-term Safety (12 Months) of the Combination of Aliskiren 300 mg and Hydrochlorothiazide 25 mg |
|
|
| Completed | 3 | 250 | US, Canada, Europe, RoW | aliskiren | Novartis | Hypertension | 02/06 | 02/06 | | |
NCT00219063 / 2004-001061-17: A Clinical Study to Compare an Aliskiren Based Hypertensive Regimen With a Ramipril Based One Followed by a Randomized Withdrawal. |
|
|
| Completed | 3 | 844 | US | aliskiren | Novartis | Hypertension | 03/06 | 03/06 | | |
NCT00250562: A Study in Chinese Mild to Moderate Hypertensive Patients Comparing the Efficacy of Co-Diovan With Diovan. |
|
|
| Completed | 3 | 1171 | US | valsartan plus hydrochlorothiazide | Novartis | Hypertension | 06/06 | 06/06 | | |
NCT00294710: A Clinical Study to Compare Long-term Efficacy and Safety of an Aliskiren Based Regimen to a Hydrochlorothiazide Based Treatment Regimen With Optional Addition of Amlodipine |
|
|
| Completed | 3 | 976 | US, Europe | Aliskiren | Novartis | Hypertension | 07/06 | 07/06 | | |
| Completed | 3 | 607 | US | valsartan plus hydrochlorothiazide | Novartis | Hypertension | 07/06 | 07/06 | | |
NCT00311740: A Study of VAH631 in Patients With Essential Hypertension (Factorial Study) |
|
|
| Completed | 3 | 582 | Japan | Valsartan, Hydrochlorothiazide | Novartis | Hypertension | 09/06 | 09/06 | | |
NCT00360178 / 2006-001311-30: Efficacy and Safety of Valsartan Plus Hydrochlorothiazide in Fixed Dose Combination in Hypertensive Patients Not Controlled by the Free Combination of an Angiotensin Receptor Blocker Plus Hydrochlorothiazide |
|
|
| Completed | 3 | 198 | Europe | Valsartan plus Hydrochlorothiazide, Candesartan plus Hydrochlorothiazide, Amlodipine | Novartis | Hypertension | 12/06 | 12/06 | | |
NCT00327145 / 2005-005010-20: A Study to Evaluate the Combination of Valsartan and Amlodipine in Hypertensive Patients Not Controlled on Monotherapy |
|
|
| Completed | 3 | 894 | Europe | valsartan, hydrochlorothiazide, amlodipine | Novartis | Hypertension | 01/07 | 01/07 | | |
NCT00219102 / 2004-004794-28: A Clinical Study to Evaluate Safety & Efficacy of the Combination of Aliskiren, Valsartan & Hydrochlorothiazide in Diabetic Hypertensive Nonresponder Patients |
|
|
| Completed | 3 | 336 | Europe, US, RoW | aliskiren | Novartis | Hypertension, Diabetes | 05/07 | 05/07 | | |
NCT00386139 / 2005-004579-39: A Safety and Efficacy Trial of the Combination of Aliskiren / Hydrochlorothiazide (HCTZ)(300/12.5 mg and 300/25 mg) Compared to Aliskiren 300 mg in Hypertensive Patients |
|
|
| Completed | 3 | 881 | US, Europe | Aliskiren/HCTZ | Novartis | Hypertension | 07/07 | 07/07 | | |
NCT00367094: Combination of Benazepril Plus Hydrochlorothiazide in Chinese Patients With Mild to Moderate Essential Hypertension |
|
|
| Completed | 3 | 296 | RoW | Benazepril plus hydrochlorothiazide | Novartis | Hypertension | | | | |
| Completed | 3 | 632 | Europe | olmesartan medoxomil, amlodipine, hydrochlorothiazide | Sankyo Pharma Gmbh | Essential Hypertension | | 08/07 | | |
| Completed | 3 | 1979 | Europe, RoW | Candesartan cilexetil, ATACAND, Hydrochlorothiazide, HCTZ | AstraZeneca | Hypertension | 08/07 | 10/07 | | |
NCT00387517 / 2005-004580-40: Safety/Efficacy of Combo Therapy With Aliskiren & Hydrochlorothiazide vs Therapy With Hydrochlorothiazide Alone in Patients With Hypertension |
|
|
| Completed | 3 | 726 | US, Europe | Aliskiren/HCTZ | Novartis | Hypertension | 08/07 | 08/07 | | |
NCT00338936: Long Term Study of VAH631 in Patients With Essential Hypertension (Extension From B1303 Study) |
|
|
| Completed | 3 | 362 | Japan | Valsartan + Hydrochlorothiazide | Novartis | Hypertension | 09/07 | 09/07 | | |
NCT00396656 / 2005-003958-94: Safety and Efficacy of Valsartan vs Atenolol and Hydrochlorothiazide Combination on Blood Flow in Hypertensive Patients |
|
|
| Completed | 3 | 30 | Europe | Atenolol, Hydrochlorothiazide (HCTZ)), Valsartan | Novartis | Hypertension | 12/07 | 12/07 | | |
NCT00523744 / 2007-001374-87: Efficacy and Safety of Valsartan and Amlodipine (± HCTZ) in Adults With Moderate, Inadequately Controlled Hypertension |
|
|
| Completed | 3 | 257 | Europe, RoW | Amlodipine, Olmesartan medoxomil, Amlodipine+valsartan, Exforge, Hydrochlorothiazide, Sandoz | Novartis | Hypertension | 12/07 | 12/07 | | |
NCT00263003: Irbesartan/Hydrochlorothiazide and Irbesartan in the Treatment of Mild to Moderate Hypertension |
|
|
| Completed | 3 | 40 | RoW | Irbesartan/hydrochlorothiazide, Irbesartan | Sanofi | Hypertension | | | | |
ACCOMPLISH, NCT00170950: Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension |
|
|
| Terminated | 3 | 11506 | Europe, US | Benazepril/amlodipine 20/5 mg - Dose Level 1 from Day 1 to Month 1, Benazepril/amlodipine 40/5 mg - Dose Level 2 from Month 1 to Month 2, Benazepril/amlodipine 40/10 mg - Dose Level 3 from Month 2 to Month 3 and thereafter, Benazepril/hydrochlorothiazide 20/12.5 mg - Dose Level 1 from Day 1 to Month 1, Benazepril/hydrochlorothiazide 40/12.5 mg - Dose Level 2 from Month 1 to Month 2, Benazepril/hydrochlorothiazide 40/25 mg - Dose Level 3 from Month 2 to Month 3 and thereafter | Novartis | Hypertension | 01/08 | 05/08 | | |
NCT00434967 / 2006-003963-30: Antihypertensive Efficacy and Safety of Candesartan/HCT 32/25 mg in Comparison With Individual Components and Placebo |
|
|
| Completed | 3 | 2207 | Europe, RoW | Candesartan cilexetil, ATACAND, Hydrochlorothiazide, HCTZ, Candesartan/HCT 32/25 mg | AstraZeneca | Hypertension | 01/08 | 01/08 | | |
NCT00547300: Study to Evaluate Symptoms in Patients Treated With Nebivolol or Metoprolol Extended-release (ER) for Hypertension |
|
|
| Terminated | 3 | 49 | US | Metoprolol ER, Nebivolol | Forest Laboratories, Mylan Laboratories | Hypertension | 01/08 | 01/08 | | |
NCT00142584: Evaluation of the Long-term Safety and Tolerability of Metoprolol Versus Nebivolol in Patients With Hypertension |
|
|
| Completed | 3 | 336 | US | Nebivolol (NEB), Metoprolol (MET) | Mylan Bertek Pharmaceuticals | Hypertension | 03/08 | 03/08 | | |
NCT00548067: Pharmacokinetic Drug Interaction Study Following Co-administration of Valsartan, Hydrochlorothiazide and Amlodipine in Patients With Hypertension |
|
|
| Completed | 3 | 111 | RoW | Valsartan/hydrochlorothiazide (HCTZ), Valsartan/amlodipine, Amlodipine/hydrochlorothiazide(HCTZ), Valsartan/amlodipine/hydrochlorothiazide(HCTZ) | Novartis | Hypertension | | 03/08 | | |
NCT00402103: An Assessment of Long Term Safety of the Combination of Aliskiren / Amlodipine in Patients With High Blood Pressure |
|
|
| Completed | 3 | 556 | US, Europe, RoW | Aliskiren, Amlodipine, Hydrochlorothiazide | Novartis | Hypertension | 04/08 | 04/08 | | |
NCT00386607: A Safety and Tolerability Study of the Combination of Aliskiren/Valsartan in Patients With High Blood Pressure, Followed by Long-term Safety and Tolerability of Aliskiren, Valsartan and Hydrochlorothiazide. |
|
|
| Completed | 3 | 601 | US, Canada, Europe | Aliskiren, Valsartan, Hydrochlorothiazide (HCTZ) | Novartis | Hypertension | 07/08 | 07/08 | | |
NCT00649389: Safety and Efficacy Study of a Triple Combination Therapy in Subjects With Hypertension |
|
|
| Completed | 3 | 2500 | US | Olmesartan medoxomil, Benicar, Amlodipine, Norvasc, Hydrochlorothiazide | Daiichi Sankyo, Inc. | Hypertension | 04/09 | 12/09 | | |
ACQUIRE, NCT00705575 / 2008-000862-21: Efficacy and Safety of the Combination Aliskiren (300 mg) and Hydrochlorothiazide (25mg) to Aliskiren (300mg) Monotherapy in Patients With Staged II Hypertension |
|
|
| Completed | 3 | 688 | US, Europe, RoW | Aliskiren/hydrochlorothiazide (HCTZ) (300/25 mg), Aliskiren (300 mg) | Novartis | Hypertension | 04/09 | 04/09 | | |
2008-004242-83: A randomized, 32 week double-blind, parallel-group, multicenter study to compare the efficacy and safety of initiating treatment with combination (aliskiren/amlodipine) therapy in comparison with the sequential add-on treatment strategies in patients with essential hypertension. |
|
|
| Completed | 3 | 1236 | Europe, RoW | Hydrochlorothiazide 12.5 mg capsules, Film-coated tablet, Capsule, hard, Rasilez, Norvasc | Novartis Pharma Services AG | hypertension | | | | |
| Completed | 3 | 10251 | US, Canada | Anti-hyperglycemic Agents, glimepiride (Amaryl), metformin (Glucophage), repaglinide (Gluconorm, Prandin), rosiglitazone (Avandia), pioglitazone (Actos), human regular insulin (Novolin ge Toronto), human NPH (Novolin N), human mixed (Novolin 70/30), human isophane (Novolin ge NPH), human 30/70 (Novolin ge 30/70), insulin aspart (NovoRapid, NovoLog), insulin detemir (Levemir), human regular insulin (Novolin R), insulin glargine (Lantus), Acarbose, Anti-hypertensive Agents, benazepril (Lotensin, Zestril, Altace), chlorthalidone (Thalitone), metoprolol (Toprol XL), diltiazem (Tiazac), plendil (Felodipine), terazosin (Hytrin), candesartan (Atacand), valsartan (Diovan), furosemide, reserpine, hydralazine, carvedilol (Coreg), triamterene / hydrochlorothiazide (Dyazide), metoprolol / hydrochlorothiazide(Lopressor HCT), benazepril / hydrochlorothiazide (Lotensin HCT), lisinopril / hydrochlorothiazide (Zestoretic), candesartan / hydrochlorothiazide (Atacand HCT), valsartan / hydrochlorothiazide (Diovan HCT), amlodipine / benazepril (Lotrel), Blinded fenofibrate or placebo plus simvastatin, fenofibrate (Tricor) | National Heart, Lung, and Blood Institute (NHLBI), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute on Aging (NIA), National Eye Institute (NEI), Centers for Disease Control and Prevention | Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia, Hypertension, Diabetes Mellitus, Type 2, Diabetes Mellitus, Coronary Disease | 06/09 | 12/12 | | |
| Completed | 3 | 1191 | US, Canada, Europe, RoW | Aliskiren, Amlodipine, Hydrochlorothiazide (HCTZ), Placebo | Novartis | Hypertension | 08/09 | 08/09 | | |
| Completed | 3 | 186 | Europe | Candesartan+HCTZ - Phase 1, Aliskiren+HCTZ - Phase 2, Aliskiren+HCTZ+amlodipine - Phase 3 | Novartis | Hypertension | 08/09 | 08/09 | | |
NCT00667719 / 2008-001242-10: A Long Term Safety Study to Test the Combination of Aliskiren/ Amlodipine / Hydrochlorothiazide in Participants With Essential Hypertension |
|
|
| Completed | 3 | 564 | Europe, US, RoW | Aliskiren, Amlodipine, Hydrochlorothiazide | Novartis | Essential Hypertension | 10/09 | 10/09 | | |
NCT00818883: Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone in Participants With Moderate to Severe Hypertension |
|
|
| Completed | 3 | 609 | US, RoW | Azilsartan medoxomil and chlorthalidone, TAK-491, TAK-491CLD, Azilsartan medoxomil and hydrochlorothiazide | Takeda | Essential Hypertension | 11/09 | 11/09 | | |
NCT00459056: The Vascular Effects of Carvedilol Controlled Release (CR) in Abdominally Obese Hypertensive Patients |
|
|
| Completed | 3 | 25 | US | Carvedilol CR + Lisinopril, Prinivil, Coreg, Lisinopril + HCTZ, Hydrochlorothiazide | St. Paul Heart Clinic, GlaxoSmithKline | Abdominal Obesity, Hypertension | 05/10 | 05/10 | | |
NCT00695955: One-Year Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension |
|
|
| Completed | 3 | 669 | US, RoW | Azilsartan medoxomil with or without add-on chlorthalidone, TAK-491, Edarbi, Azilsartan medoxomil with or without add-on hydrochlorothiazide | Takeda | Hypertension | 05/10 | 05/10 | | |
ACCELERATE, NCT00797862: Aliskiren and the Calcium Channel Blocker Amlodipine Combination as an Initial Treatment Strategy for Hypertension |
|
|
| Completed | 3 | 1254 | Canada, Europe, RoW | Amlodipine, Norvasc, hydrochlorothiazide, Esidrix, HydroDIURIL, Oretic, Ezide, Hydro-Par, Aliskiren, SPA 100 | Novartis | Hypertension | 11/10 | 11/10 | | |
NCT01258673: A Clinical Study to Evaluate Efficacy and Safety of Fimasartan/Hydrochlorothiazide Combination-therapy |
|
|
| Completed | 3 | 263 | RoW | Fimasartan/HCTZ combination, Fimasartan | Boryung Pharmaceutical Co., Ltd, Seoul National University Hospital, The Catholic University of Korea, Korea University Guro Hospital, DongGuk University, Seoul National University Bundang Hospital, Samsung Medical Center, Asan Medical Center, Gangnam Severance Hospital, Severance Hospital, Ajou University, Chonbuk National University Hospital, Cheil General Hospital and Women's Healthcare Center, Chonnam National University Hospital, Hanyang University, Yonsei University, Ilsan-Paik Hospital, SMG-SNU Boramae Medical Center, Kyung Hee University Hospital | Essential Hypertension | 12/11 | | | |
NCT01415505: Combination of Nebivolol and Valsartan Given as Free Tablets for Stage 1 or Stage 2 Hypertension |
|
|
| Completed | 3 | 812 | US | Nebivolol, Valsartan and Hydrochlorothiazide | Forest Laboratories | Hypertension | 01/13 | 04/13 | | |
FIRME-1, NCT02466490: Efficacy and Safety of Fimasartan Alone or Combined With HCTZ in Mexican Patients With Essential Hypertension |
|
|
| Completed | 3 | 272 | RoW | Fimasartan, Arakhor, Kanarb, Fimasartan; Hydrochlorothiazide, Diarakhor, Kanarb plus | Stendhal Americas, S.A. | Hypertension, Essential | 02/14 | 02/14 | | |
| Completed | 3 | 150 | Europe, RoW | Valsartan, VAL489, amlodipine, Hydrochlorothiazide, HCTZ | Novartis Pharmaceuticals | Hypertension, Chronic Kidney Disease | 09/15 | 09/15 | | |
2004-000703-18: A multicenter, double-blind, randomized study comparing the efficacy of combination therapy of Eprosartan respectively Ramipril with low-dose Hydrochlorothiazide and Moxonidine on blood pressure levels in patients with hypertension and associated diabetes mellitus type 2 (ASTRID – Antihypertensive treatment of Systolic/diastolic hypertension comparing Teveten and Ramipril in type 2 Diabetics). |
|
|
| | 3 | 64 | Europe | Tevetens, Acovil, Moxon, Hydrochlorothiazide, TEVETENS, ACOVIL, MOXON, HYDROCHLOROTHIAZIDE, TEVETENS, ACOVIL, MOXON, HYDROCHLOROTHIAZIDE | SOLVAY PHARMACEUTICALS GMBH, SOLVAY PHARMA | Essential hypertension with associated Diabetes Mellitus type 2. | | | | |
2004-002077-23: Efficacy and safety of Olmesartan medoxomil in elderly patients with mild to moderate hypertension |
|
|
| | 3 | 80 | Europe | OLMESARTAN MEDOXOMIL, RAMIPRIL, ZOFENOPRIL CALCIUM, HYDROCHLOROTHIAZIDE, Cs-866, Omesar 10mg, Omesar 20mg, Omesar 40mg, Tritrace, TRITACE 5mg, ZOFENIL 15 mg, HCT Hexal 12.5 mg, Omesar 10mg, Omesar 20mg, Omesar 40mg, Tritrace, TRITACE 5mg, ZOFENIL 15 mg, HCT Hexal 12.5 mg | MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG S.A. | Male or female outpatients, aged 65-89 years, with mild to moderate essential hypertension (sDBP>=90mmHg and sSBP>=140mmHg) | | 03/09 | | |
2006-003629-98: A 54-week, randomized, open-label, multicenter study to assess the long-term safety and tolerability of the combination of aliskiren 300 mg/ amlodipine 10 mg in patients with essential hypertension |
|
|
| Completed | 3 | 100 | Europe, RoW | Aliskiren, Amlodipine, Hydrochlorothiazide, SPP100, Norvasc 5mg, Esidrex, Norvasc 5mg, Esidrex | Novartis Pharma AG, Novartis Pharma Services AG | Hypertension | | 03/08 | | |
2008-002439-33: EFFICACY AND SAFETY OF ZOFENOPRIL + HYDROCHLOROTHIAZIDE COMBINATION VS IRBESARTAN + HYDROCHLOROTHIAZIDE COMBINATION IN ESSENTIAL HYPERTENSIVE PATIENTS NOT CONTROLLED BY PREVIOUS MONOTHERAPY |
|
|
| Completed | 3 | 84 | Europe | ZOFENOPRIL 30 MG + HYDROCHLOROTHIAZIDE 12.5 MG, ZOFENOPRIL 30 MG, IRBESARTAN 150 MG + HYDROCHLOROTHIAZIDE 12.5 MG, IRBESARTAN 150 MG, BIFRIZIDE, BIFRIL, COAPROVEL, APROVEL, BIFRIZIDE, BIFRIL, COAPROVEL, APROVEL | MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG S.A., MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG SA | Patients with essential hypertension and with at least one additional cardiovascular risk factor, not controlled by a previous monotherapy | | 10/10 | | |
2008-007681-30: EFFICACY AND SAFETY OF ZOFENOPRIL + HYDROCHLOROTHIAZIDE COMBINATION VS. IRBESARTAN + HYDROCHLOROTHIAZIDE COMBINATION IN ESSENTIAL HYPERTENSIVE PATIENTS NOT CONTROLLED BY PREVIOUS MONOTHERAPY |
|
|
| Completed | 3 | 446 | Europe | BIFRIZIDE, BIFRIL, BIFRIZIDE, BIFRIL | LUSOFARMACO | Essential hypertension | | | | |
2009-012993-10: EFFICACY AND SAFETY OF ZOFENOPRIL+HYDROCHLOROTHIAZIDE COMBINATION VS. IRBESARTAN+HYDROCHLOROTHIAZIDE COMBINATION IN METABOLIC SYNDROME PATIENTS WITH ESSENTIAL HYPERTENSION NOT CONTROLLED BY PREVIOUS MONOTHERAPY |
|
|
| Completed | 3 | 306 | Europe | Capsule, hard | A. MENARINI I.F.R. | PATIENTS affected by METABOLIC SYNDROME WITH ESSENTIAL HYPERTENSION NOT CONTROLLED BY PREVIOUS MONOTHERAPY | | | | |
2006-002621-23: A 54-week, open-label, multicenter study to assess the long-term safety and tolerability of the combination of aliskiren 300mg/ valsartan 320 mg in patients with essential hypertension. |
|
|
| | 3 | 100 | Europe | Aliskiren, Valsartan, Hydrochlorothiazide, SPP100, VAL489, Diovan 160 mg comprimidos recubiertos con película, Esidrex, Diovan 160 mg comprimidos recubiertos con película, Esidrex | Novartis Pharma Services Ag, Novartis Pharma Services AG, Novartis Farmaceutica S.A. | Hypertension | | 01/08 | | |
NCT02277691: A Phase III Long-term Study of TAK-536TCH in Participants With Essential Hypertension |
|
|
| Completed | 3 | 341 | Japan | TAK-536TCH tablet, TAK-536CCB tablet, HCTZ 12.5 mg tablet | Takeda | Essential Hypertension | 04/16 | 04/16 | | |
| Unknown status | 3 | 300 | Europe | Peri, Perindopril, HCTZ, Hydrochlorothiazide | Ospedale San Raffaele | Hypertension | 03/18 | 11/18 | | |
NCT04952051: Enalapril Folic Acid Tablets Combined With CCB or Diuretic to Prevent Stroke in Patients With Type H Hypertension |
|
|
| Completed | 3 | 1000 | RoW | Enalapril Folic Acid Tablets Combined With amlodipine, Enalapril Folic Acid Tablets Combined With hydrochlorothiazide | Second Affiliated Hospital, School of Medicine, Zhejiang University, National Clinical Research Center, Southern Medical University, Ningbo Yinzhou Community Health Service Center | Hypertension | 07/19 | 07/20 | | |
| Completed | 3 | 416 | Europe | Placebo oral capsule, 12.5 mg hydrochlorothiazide, 25.0 mg hydrochlorothiazide, 50.0 mg hydrochlorothiazide | Insel Gruppe AG, University Hospital Bern | Nephrolithiasis | 12/21 | 04/22 | | |
| Completed | 3 | 20723 | US | Hydrochlorothiazide (HCTZ), HCTZ, Chlorthalidone (CTD), CTD | VA Office of Research and Development | Hypertension | 10/22 | 12/22 | | |
NCT03298802: Postpartum Management of Hypertension in Pregnancy With Hydrochlorothiazide |
|
|
| Recruiting | 3 | 612 | US | Hydrochlorothiazide 50mg Tablet, HydroDIURIL, Microzide, Esidrix, Oretic, Placebo Tablet, sugar pill | The University of Texas Medical Branch, Galveston | Pre-Eclampsia, Gestational Hypertension, Superimposed Pre-Eclampsia, Hypertension, Pregnancy-Induced, Postpartum Pregnancy-Induced Hypertension, Postpartum Preeclampsia | 08/24 | 08/24 | | |
OPTION TREAT, NCT05920005: Candesartan Cilexetil + Chlorthalidone + Amlodipine Versus Exforge HCT®️ for Systemic Arterial Hypertension |
|
|
| Recruiting | 3 | 698 | RoW | candesartan cilexetil + chlorthalidone + amlodipine, Exforge HCT® (valsartan 160mg + hydrochlorothiazide 12.5mg + amlodipine 5mg) | Hospital Israelita Albert Einstein, Libbs Farmacêutica LTDA | Hypertension | 12/23 | 07/24 | | |
| Not yet recruiting | 3 | 300 | Europe | Hydrochlorothiazide 25 mg, Placebo | University Medical Center Groningen | ADPKD | 07/28 | 07/29 | | |
| Terminated | 2/3 | 10 | Europe | Hydrochlorothiazide | Assistance Publique - Hôpitaux de Paris | Dent's Disease, Nephrolithiasis | 12/05 | 12/05 | | |
NCT02072330: Study to Evaluate the Efficacy and Safety of Combined Administration of TAK-536CCB and Hydrochlorothiazide in Patients With Grade I or II Essential Hypertension. |
|
|
| Completed | 2/3 | 353 | Japan | TAK-536CCB, Fix-dose combination of Azilsartan and Amlodipine, TAK-536CCB + Hydrochlorothiazide, Hydrochlorothiazide and fix-dose combination of Azilsartan and Amlodipine, Hydrochlorothiazide | Takeda | Grade I or II Essential Hypertension | 12/13 | 12/13 | | |
